Cavé, C.

Publications

P312

ChemMedChem 2026, 21, e70338.

Bicyclic Lactams From Chiral Imines: Synthesis, Structural Optimization, and Biological Evaluation of Promising Antileishmanial Agents.

Sagne, S. Cojean, S. Diallo, R. O. Barbosa, E.G. Weber, K.C. da Silva, M.C. Sambou, O. Tomasoni, C. Bonnet, J. Pagniez, F. Cavé, C. Gassama, A Marchand, P.

https://doi.org/10.1002/cmdc.70338

P300

RSC Med. Chem. 2025, 16, 3746–3763. 

 Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy

Tisseur, L. Logé, C. Cojean, S. Gassama, K. Karcher, L. Pagniez, F. Cavé, C. Bernadat, G. Loiseau, P. M. Bach, S. Thiéfaine, J. Bonnet, J. Picot, C. Tomasoni, C. Leclercq, O. Baratte, B. Robert, T. Le Pape, P. Rachidi, N. Bazin, M.-A. Marchand, P.

https://doi.org/10.1039/D5MD00257E

P290

ChemMedChem. 2025, 20, e202400862.

Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.

Tisseur, L. Cojean, S. Gassama, K. Logé, C. Pagniez, F. Cavé, C. Bernadat, G. Loiseau, P.M. Bach, S. Thiéfaine, J. Picot, C. Tomasoni, C. Leclercq, O. Baratte, B. Robert, T. Le Pape, P. Rachidi, N. Bazin, M.-A. Marchand, P.

https://doi.org/10.1002/cmdc.202400862

P231

Eur. J. Med. Chem. 2021, 210, 112956.

In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.

Bazin, M.-A. Cojean, S. Pagniez, F. Bernadat, G. Cavé, C. Ourliac-Garnier, I. Nourrisson, M.-R. Morgado, C. Picot, C. Leclercq, O. Baratte, B. Robert, T. Späth, G.F. Rachidi, N. Bach, S. Loiseau, P.M. Le Pape, P. Marchand, P.

doi: 10.1016/j.ejmech.2020.112956